Drug Profile
Natural killer cell therapy - Shanghai iCELL Biotechnology/The Second Affiliated Hospital of Fujian Medical University
Latest Information Update: 10 Oct 2021
Price :
$50
*
At a glance
- Originator Shanghai iCELL Biotechnology
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Spinal cord disorders
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for phase-I development in Spinal cord disorders(In the elderly, In adults) in China (IV, Injection)
- 01 Jul 2016 Phase-I clinical trials in Spinal cord disorders (In adults, In the elderly) in China (IV) (NCT02961712)